Gold prices edge higher on raised Fed rate cut hopes
On Tuesday, Jones Trading analysts reiterated their Buy rating for Rapport Therapeutics stock (NASDAQ:RAPP) with a price target of $42.00. This follows the company’s Investor & Analyst Day event, where key developments were discussed.
During the event, Rapport Therapeutics provided insights into the upcoming RAP-219 data readout for refractory focal epilepsy. The company, which maintains a healthy current ratio of 31.01 and holds more cash than debt, outlined expectations for a successful outcome in the topline Phase IIa results, anticipated in September 2025.
A notable segment of the event was a fireside chat with KOL and trial investigator Jacqueline French, M.D. Dr. French emphasized her strong belief that reducing long episodes is a clear sign of improvement in patients with focal epilepsy. She also noted that the Phase IIa results are likely to be applicable to later stages of clinical trials. Get access to 8 more exclusive InvestingPro Tips and comprehensive financial metrics to make better informed investment decisions.
The reaffirmed Buy rating and price target reflect the analysts’ confidence in the potential of Rapport Therapeutics’ ongoing research and development efforts, with analyst targets ranging from $28 to $42 per share.
In other recent news, Rapport Therapeutics has been in the spotlight with several significant developments. Stifel analysts reiterated their Buy rating for the company, maintaining a price target of $35.00. This decision follows updates on the RAP-219 phase 2a study in focal onset seizures (FOS), where a high concordance rate was observed between long episodes and EEG seizures. Citizens JMP analysts also maintained a Market Outperform rating with a $28 price target, emphasizing the potential of RAP-219 in treating focal epilepsy. Rapport Therapeutics completed enrollment for the RAP-219 trial and expects to reveal proof-of-concept results in September.
Additionally, the company appointed Dr. Jeffrey Sevigny as its new chief medical officer, bringing over 15 years of experience in drug development. Dr. Sevigny’s role will focus on advancing the clinical strategy for RAP-219, which is under investigation for several conditions, including focal epilepsy and diabetic peripheral neuropathic pain. These developments underscore Rapport Therapeutics’ ongoing efforts to enhance its drug pipeline and clinical programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.